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Introduction {#sec001}
============

Dengue, a self-limiting illness accompanied by high fever, headache, muscle and joint pains, vomiting or rash, is a mosquito borne viral disease transmitted by female mosquitoes of the species *Aedes aegypti* or *Aedes albopictus* \[[@pone.0237141.ref001]\]. The causative agent, dengue virus (DENV), is a positive-sense single-stranded RNA virus belonging to the family *Flaviviridae* which comprises of 4 distinct but closely related serotypes named DENV-1, DENV-2, DENV-3 and DENV-4 \[[@pone.0237141.ref002]\]. Although dengue can be asymptomatic or presented mostly as an acute mild febrile illness, 0.05% of the cases progressing to severe dengue had potentially fatal complications such as plasma leakage, severe bleeding or organ impairment \[[@pone.0237141.ref003]\]. Vascular leakage, the hallmark of severe dengue usually involves the loss of function or increased permeability of the endothelium that lines the pleural and peritoneal cavities \[[@pone.0237141.ref004]\]. The pathogenesis of severe dengue is theorized to be due to the intricate interactions between viral factors, host genetics and host immune activation \[[@pone.0237141.ref005]\]. Dengue viral proteins such as the structural and non-structural proteins have been demonstrated to differentially modulate host immune responses, including antibody neutralization activity \[[@pone.0237141.ref006]\], complement alternative pathway \[[@pone.0237141.ref007]\], T cell activation \[[@pone.0237141.ref008], [@pone.0237141.ref009]\] and the production of pro-inflammatory cytokines \[[@pone.0237141.ref010]--[@pone.0237141.ref012]\], which play a major role in the enhancement of the disease.

The RNA genome of DENV is translated into a long polypeptide that is further cleaved and processed by viral and host proteases into three structural proteins (envelope, capsid protein and precursor membrane) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) \[[@pone.0237141.ref013]\]. Being one of the most conserved and enigmatic protein among the non-structural proteins, NS1 is critically required for RNA replication and the production of infectious viral particles \[[@pone.0237141.ref014]\]. It is secreted into the blood circulation of the host during dengue virus infection and has been used as a viral marker for early diagnosis of dengue for decades \[[@pone.0237141.ref015]\]. However, NS1-induced vascular leakage was discussed only in recent years and the contribution of NS1 to vascular leakage as well as the mechanism of pathogenesis remains controversial. Several studies reported that the level of NS1 was higher in patients with severe dengue (SD) \[[@pone.0237141.ref016], [@pone.0237141.ref017]\] and it appears to contribute to disease severity by inducing IL-10 production by monocytes \[[@pone.0237141.ref018]\], activating immune cells via toll-like receptor 4 \[[@pone.0237141.ref019]\] or disrupting the endothelial glycocalyx components leading to increased vascular permeability \[[@pone.0237141.ref020]\]. On the other hand, studies also showed that low level of NS1 can also be associated with more severe manifestations \[[@pone.0237141.ref021]\] and the NS1 positivity did not correlate with severe pathologies \[[@pone.0237141.ref022]\]. These contradictory findings obscure the role of NS1 in inducing vascular leakage observed in patients with SD, leaving an unaddressed research gap for further studies.

The immunopathogenesis of severe dengue is mediated mainly by humoral immune response supported by the evidence of exaggerated cytokine production from antibody-dependent enhancement and complement activation by antigen-antibody complexes \[[@pone.0237141.ref023]\]. Although individuals with secondary infections are believed to have a higher risk of developing severe dengue due to the presence of cross-reactive non-neutralising antibodies from primary infection, severe manifestations have also been reported in patients with primary infections \[[@pone.0237141.ref024]\] with increased level of inflammatory cytokines \[[@pone.0237141.ref025], [@pone.0237141.ref026]\]. The infecting serotypes also contribute to the risk of severe dengue, for instance, infection with DENV-3 resulted in a greater percentage of severe cases for primary infection in Southeast Asia (SEA) region, while for secondary infection, DENV-2, DENV-3 and DENV-4 from SEA region, as well as DENV-2 and DENV-3 from the non-SEA regions displayed greater percentages of severe cases \[[@pone.0237141.ref024]\]. Despite the immune status of the host, abundant evidences suggested that high levels of inflammatory cytokines contribute to the development of severe manifestations in DENV infection \[[@pone.0237141.ref027], [@pone.0237141.ref028]\]. The production of unfavourable cytokines from massive immune activation of monocytes, macrophages and T cells play an important role in causing endothelial dysfunction and increased vascular permeability. However, contradictory findings have also been reported on the correlation between cytokine levels and disease severity in dengue patients. Several cytokines such as IFN-γ, TNF-α, IL-4, IL-10, IP-10 and VCAM-1 have been shown to be elevated in patients with SD \[[@pone.0237141.ref029]--[@pone.0237141.ref031]\] while in other studies, the same cytokines such as IFN-γ and TNF-α showed no difference in levels between patients with mild dengue fever and severe dengue \[[@pone.0237141.ref027], [@pone.0237141.ref032]\]. Despite the ambiguous role of inflammatory cytokines in determining disease severity, the potential use of certain cytokines as biomarkers to predict the progression of severe dengue has been highlighted \[[@pone.0237141.ref033], [@pone.0237141.ref034]\]. This intention emphasized the importance of research on dengue immunopathogenesis for successful identification of biomarkers that are expressed differentially in severe dengue compared to other categories of dengue.

Since endothelial cells have been proposed to be prominently involved in the immunopathogenesis of plasma leakage and haemorrhagic manifestations in severe dengue \[[@pone.0237141.ref035]\], it is important to be able to investigate the real time changes of the barrier function of the cells *in* vitro under the simulation of DENV infection. An electrical-substrate impedance sensing (ECIS) technique has been used for this purpose. ECIS is a real time approach to monitor barrier function or permeability of cell monolayers electrically using different frequencies of alternative current (AC) for constant measurement. High frequency capacitance signifies the establishment of a confluent cell layer and a low frequency resistance represents the formation of para-cellular passage, where the combination of both parameters into impedance, using the mathematical model in ECIS software, provides an insight towards the barrier function of the cells. An increase in impedance would indicate junctional tightening and a reduction would indicate a loss of barrier function, which in our case would indicate a vascular leakage as endothelial cells were used \[[@pone.0237141.ref036]\].

Hence, this study aims to investigate the role of the viral factor, specifically the NS1 protein and the host factors, in term of the expression of inflammatory cytokines and immune-related metabolites in contributing to the degree of severity of dengue virus infection. We investigated the effect of NS1 at varying levels to the barrier function of microvascular endothelium using ECIS, as well as the effect of NS1 in the presence of other host factors in patient sera from three categories of disease severity including dengue without warning signs, dengue with warning signs and severe dengue, in causing vascular leakage in microvascular endothelium. After determining the clinical relevance of viral factor (NS1) in inducing vascular leakage, we assessed the cytokine expression profile and the metabolomics profile of these patients in comparison to the expression profile of healthy individuals to identify host factors that may underlie dengue disease processes.

Materials and methods {#sec002}
=====================

Sample collection and selection {#sec003}
-------------------------------

A total of 40 archived serum samples previously collected under ethical statement of IRB reference number 926.4 from UMMC Medical Research Ethics Committee (MREC) with written informed consent were used in this study. Among the 40 samples, 30 samples were from anonymized patients diagnosed with dengue virus infection, while 10 samples were collected from volunteered healthy individuals. The clinical data were recorded during blood collection and the disease severity was categorized into dengue without warning signs (DWOWS), dengue with warning signs (DWWS) and severe dengue (SD) according to the guidelines on case classification provided by WHO in 2009 ([S1 Table](#pone.0237141.s001){ref-type="supplementary-material"}) \[[@pone.0237141.ref003]\]. The serum samples were subjected to DENV reverse transcriptase polymerase chain reaction (RT-PCR) with iTaq^™^ Universal SYBR^®^ Green One-step Kit (Bio-rad Laboratories, Hercules, CA, USA), Panbio Dengue Early ELISA (Alere, Waltham, MA, USA), SD BIOLINE Dengue IgM capture ELISA (Alere) and hemagglutination inhibition (HI) test to confirm dengue virus infection. For ECIS measurement, five samples were selected randomly for each dengue category from a panel of NS1 and IgM positive samples to assess the effect of NS1 levels by setting the presence of IgM antibodies as a constant variable. Five samples that were dengue positive from laboratory tests were selected randomly and a total of 10 samples including those used for ECIS measurement for each dengue category were included for cytokine and metabolomics profiling. Ten samples from healthy individuals were selected and confirmed with negative results from laboratory tests.

Cell culture {#sec004}
------------

Three microvascular endothelial cell lines including primary human dermal microvascular endothelial cells (HDMEC) (Sciencell, Carlsbad, CA, USA), primary human pulmonary microvascular endothelial cells (HPMEC) (Sciencell) and primary human retinal microvascular endothelial cells (HRtMEC) (CSC, Tysons, VA, USA) were cultured as *in vitro* models for dengue virus infection. The cells were maintained at 37°C with 5% CO~2~ supplemented with endothelial cell growth medium (ECM) (Sciencell) for HDMEC and HPMEC, and CSC complete medium (CSC) for HRtMEC.

Electrical cell-substrate impedance sensing (ECIS) {#sec005}
--------------------------------------------------

The three MEC lines were grown to a confluent monolayer in an eight-well electrode array (8W10E+) (Applied Biophysics, Troy, NY, USA) in triplicates prior to the treatment with NS1 antigen or serum samples for ECIS measurement. The NS1 antigen (Bio-rad) used is a recombinant dengue virus serotype 1 NS1 protein of sequence strain Nauru/Western Pacific/1974 expressed in 293 human cells. It is produced with a C-terminal 6x His-tag and at a purity of \>95% by SDS PAGE analysis diluted in buffer solution Dulbecco's phosphate buffered saline, which was further diluted during the experiment using the respective media of each cell line used. High (1ng/mL), medium (10pg/mL) and low (0.1pg/mL) levels of recombinant NS1 antigen were selected based on the values obtained in NS1 ELISA test that corresponds to the level of NS1 detected in the selected serum samples. The cells were treated with NS1 antigens at the three selected concentrations, five serum samples that had varying levels of NS1 antigen from each category (DWOWS, DWWS, SD) and five healthy individuals (HC). The real time changes in impedance (resistance and capacitance) induced in the MECs after treatment was detected using multiple alternative current (AC) frequencies in an ECIS Zθ 16-well array station (Applied Biophysics) for 72 hours. The raw data was first normalized to cell-free wells to eliminate background signals, followed by normalization to 0 hours post infection (hpi) in the untreated cells. The standard error of mean between the triplicates was determined and presented at regular intervals.

Cytokine profiling {#sec006}
------------------

The level of 14 commonly studied cytokines, chemokines, adhesion molecules and growth factors (CCL2, CCL5, CCL20, CD25, CXCL1, CXCL6, CXCL9, CXCL10, CXCL11, IL-18, TNF-a, VEGF-A, HMGB-1 and ICAM-1) in the 40 selected serum samples were assessed using the Human Magnetic Luminex multiplex screening assay based on flow cytometric analysis of magnetic antibody-coated microbeads targeting the analytes of interest (R&D Systems, Minneapolis, MN, USA). These 14 cytokines have been shown to have a role during dengue virus infection in terms of endothelial immune activation \[[@pone.0237141.ref034], [@pone.0237141.ref037], [@pone.0237141.ref038]\] and among them, CCL2, CCL5, CCL20, CXCL1, CXCL10, CXCL11, TNF-α and ICAM-1 have been reported to be produced directly by DENV-infected microvascular endothelial cells \[[@pone.0237141.ref039]\]. The precision and reproducibility of the assays were assured by calculating the coefficient of variance of the replicates. The significant differences of the cytokine expression profile between the categories were determined using student's T test.

Untargeted metabolomics {#sec007}
-----------------------

The metabolic profiling analysis of the 40 selected serum samples was conducted using quadrupole time of flight liquid chromatography mass spectrometry (QTOF-LCMS) technique. Protein precipitation and metabolite extraction from serum samples was performed by adding 3 volumes of cold (-20°C) mixture of methanol and ethanol (volume ratio of 1:1) to 1 volume of serum. Samples were vortex-mixed and stored at -20°C for 5 minutes, followed by centrifugation at 16,000 × g at 4°C for 10 minutes. The pellet was removed and the supernatant was filtered through a 0.22μm nylon filter and subjected to LCMS procedure.

10μL of extracted serum sample was applied to a reversed-phase column (Agilent 959764--902, Eclipse Plus C18, 2.1x100mm, 1.8um, 600Bar) (Agilent Technologies, Santa Clara, CA, USA) in QTOF-LCMS system (Agilent 6550 iFunnel) operated at a flow rate of 0.6mL/min in positive electrospray ionization (ESI) mode. The solvents used were solvent A, water with 0.1% formic acid and solvent B, acetonitrile with 0.1% formic acid. The gradient started from 25% B to 95% B in the first 35 minutes, returned to 25% B within the next 1 minute, and maintained at 25% B for the remaining 9 minutes. Samples were analysed in one randomized run with a capillary voltage of 3000V and nebulizer gas flow rate of 10.5L/min. During the analysis, two reference masses: 121.0509 m/z (C5H4N4) and 922.0098 m/z (C18H18O6N3P3F24) were continuously measured to allow constant mass correction. Data were required in positive ion mode with a full scan from 50 to 1000 m/z at a rate of 1.02 scans per second.

The raw data files obtained from QTOF-LCMS were extracted using an untargeted batch-processing feature extraction software, MassHunter Profinder (Agilent) to generate processed .cef file to be input into a chemometrics software, Mass Profiler Professional (Agilent) for data analysis described below \[[@pone.0237141.ref040]\]. Unsupervised principle component analysis (PCA) was performed for quality control of the samples based on the variability in the data and their possible correlation. The included data set was then reordered and grouped into HC, DWOWS, DWWS and SD. Data was prepared by filtering the frequency and abundance, aligning the parameters based on tolerances established by retention time and mass, normalizing to reduce the variability caused by sample preparation and instrument response followed by base-lining the statistical abundance across all the samples for further data analysis. Fold change of the metabolic expression in dengue groups (DWOWS, DWWS and SD) against HC was calculated and statistical analysis was performed using multivariate Welch's one-way ANOVA with Benjamini Hochberg false discovery rate for multiple group comparison. Cut-off value of fold change \> 2.0 with p-value \< 0.05 was used for selection. Selected metabolites were highlighted by calculating the prevalence of expression among the categories along with the abundance of ion detection representing the level of expression in each individual. Visualizations such as Venn diagrams, volcano plots, hierarchical complete linkage clustered heat maps, histograms and boxplots have been constructed to present the findings of the experiment. Pathway enrichment analysis was also completed based on BioCyc Database \[[@pone.0237141.ref041]\] and Human Metabolome Database \[[@pone.0237141.ref042]\] to identify metabolic pathways involved in the progression of dengue virus infection.

Results {#sec008}
=======

Samples characteristics {#sec009}
-----------------------

The clinical data and diagnostic results of twenty serum samples selected for ECIS measurement is shown in [Table 1](#pone.0237141.t001){ref-type="table"}. All the samples from HC category were DENV PCR negative, NS1 negative, IgM negative but contained low concentration of neutralizing antibodies (\<10, 10, 20). For dengue positive samples, all were DENV PCR negative with varying levels of NS1 ranging from 27.90 to 75.78 Panbio Unit. Eleven samples have a low HI titre at \<10, 10, 20 and 80, while four samples contained high level of neutralizing antibodies with HI titre of 640 and 2560. The day of illness of dengue patients ranged from 3--7 days at the time of collection. The clinical diagnosis of 40 serum samples selected for cytokine and metabolomics profiling is summarized in [Table 2](#pone.0237141.t002){ref-type="table"}. Additional five samples from each category have been added to the panel on top of the previous selected samples for ECIS study. The number of DENV PCR positive samples were one and two in categories of DWOWS and DWWS respectively. Eight of DWOWS, six of DWWS and six of SD samples were NS1 positive, while DWOWS, DWWS and SD consist of nine, eight and nine IgM positive samples, respectively. The day of illness at the time of collection ranged from 3--6 days in DWOWS, 4--6 days in DWWS and 4--7 days in SD.

10.1371/journal.pone.0237141.t001

###### The results for DENV PCR, NS1 ELISA, IgM ELISA and HI for five serum samples from each category accompanied by the day of illness.

Panbio Units were calculated based on manufacturer's protocol with a cut off value of \>11 for NS1 positive samples and \<9 for NS1 negative samples.

![](pone.0237141.t001){#pone.0237141.t001g}

  SAMPLES   CATEGORY   DENV PCR   NS1 ELISA   PANBIO UNIT   IGM ELISA   HI     DAY OF ILLNESS
  --------- ---------- ---------- ----------- ------------- ----------- ------ ----------------
  **H1**    HC         \-         \-          1.85          \-          \<10   \-
  **H2**    HC         \-         \-          2.56          \-          20     \-
  **H3**    HC         \-         \-          1.90          \-          20     \-
  **H4**    HC         \-         \-          2.00          \-          10     \-
  **H5**    HC         \-         \-          1.82          \-          \<10   \-
  **WO1**   DWOWS      \-         \+          75.78         \+          \<10   3
  **WO2**   DWOWS      \-         \+          69.80         \+          20     4
  **WO3**   DWOWS      \-         \+          58.28         \+          2560   6
  **WO4**   DWOWS      \-         \+          56.40         \+          640    6
  **WO5**   DWOWS      \-         \+          27.90         \+          20     3
  **W1**    DWWS       \-         \+          75.66         \+          2560   6
  **W2**    DWWS       \-         \+          69.91         \+          \<10   6
  **W3**    DWWS       \-         \+          54.50         \+          10     5
  **W4**    DWWS       \-         \+          39.77         \+          10     5
  **W5**    DWWS       \-         \+          38.22         \+          \<10   5
  **S1**    SD         \-         \+          69.02         \+          2560   3
  **S2**    SD         \-         \+          67.35         \+          20     4
  **S3**    SD         \-         \+          65.92         \+          10     7
  **S4**    SD         \-         \+          58.34         \+          80     4
  **S5**    SD         \-         \+          39.6          \+          20     6

10.1371/journal.pone.0237141.t002

###### The number of samples tested positive for DENV PCR, NS1 ELISA and IgM ELISA among the 10 serum samples selected for each dengue category accompanied by the day of illness.

These ten samples consisted of five previously selected samples from ECIS measurement and five serum samples randomly selected from a pool of dengue positive samples, as well as for the healthy individuals.

![](pone.0237141.t002){#pone.0237141.t002g}

  CATEGORIES   TOTAL SAMPLE NUMBER   DENV PCR POSITIVE   NS1 ELISA POSITIVE   IGM ELISA POSITIVE   DAY OF ILLNESS
  ------------ --------------------- ------------------- -------------------- -------------------- ----------------
  **HC**       10                    0                   0                    0                    \-
  **DWOWS**    10                    1                   8                    9                    3--6
  **DWWS**     10                    2                   6                    8                    4--6
  **SD**       10                    0                   6                    9                    4--7

NS1 modulates MECs barrier function in a dose dependent manner {#sec010}
--------------------------------------------------------------

The NS1 concentration of the fifteen serum samples selected for ECIS measurement were categorized into high (Panbio Unit 60--80), medium (Panbio Unit 40--60) and low (Panbio Unit 20--40) levels. The NS1 ELISA results for 1ng/mL, 10pg/mL and 0.1pg/mL of NS1 antigen are 68.7, 51.2 and 32.1 Panbio Unit respectively, representing high, medium and low level of NS1 corresponding to the level of NS1 detected in the serum samples.

The changes in the impedance of the MECs treated with three levels of NS1 were measured using ECIS system for 72 hpi and the results are presented in [Fig 1](#pone.0237141.g001){ref-type="fig"}. Dermal and retinal MECs responded in a similar manner, starting with a slight impedance reduction upon the introduction of NS1, which then increased at 12 hpi, followed by a fluctuating but progressive reduction from 24 hpi onwards. A small difference in the modulation was observed only at 60 hpi onwards between the MECs treated with three different levels of NS1, where higher level of NS1 reduced the impedance of MECs at a higher magnitude. The changes of impedance in pulmonary MECs were dose dependent. In pulmonary MECs treated with high levels of NS1, the impedance reduced drastically upon introduction of NS1 for up to 60 hours before increasing. The MECs treated with low and medium level of NS1 also showed a reduction in impedance at 0 hpi, followed by an increase at 12 hpi and 24 hpi respectively. The impedance eventually reduced at 36 hpi and recovered to control levels at 72 hpi.

![Normalized real-time impedance changes in (A) Dermal MEC, (B) Pulmonary MEC and (C) Retinal MEC treated with low (0.1pg/mL), medium (10pg/mL) and high (1ng/mL) levels of NS1 antigens. The measured impedances of the treated MECs were normalized to the un-treated cells and the standard error of mean between biological triplicates were represented as error bars.](pone.0237141.g001){#pone.0237141.g001}

The loss of microvascular barrier function in severe dengue did not correlate with NS1 level {#sec011}
--------------------------------------------------------------------------------------------

The five serum samples randomly selected from each category for the ECIS measurement consisted of samples with high (Panbio Unit 60--80), medium (Panbio Unit 40--60) and low levels (Panbio Unit 20--40) of NS1. Dermal, pulmonary and retinal MECs were incubated with all serum samples for 72 hours and the changes in impedance triggered by NS1 protein contained in the serum samples were assessed using ECIS system to investigate the modulation to MECs barrier function.

[Fig 2](#pone.0237141.g002){ref-type="fig"} shows the changes in impedance of dermal MECs representing the modulation of barrier function after the incubation with five serum samples from each of the HC, DWOWS, DWWS and SD categories. In all categories, impedance reduced immediately upon the introduction of sera, followed by an increase at 1 hpi which then peaked at 7 hpi. For HC, the impedance then maintained at a similar level as compared to the non-treated control cells, while for the other three dengue categories, most of the samples had an impedance reduction below control level indicating vascular leakage and fluctuated across the 72 hours. However, no distinct changing pattern was observed in between MECs incubated with sera at different levels of NS1 as well as sera from different categories.

![Normalized real time impedance changes in [dermal MECs]{.ul} incubated with serum samples from the category of (A) Healthy individuals (HC), (B) dengue without warning signs (DWOWS), (C) dengue with warning signs (DWWS) and (D) severe dengue (SD). Five serum samples from each dengue category consisted of samples with high NS1 level (red lines), medium NS1 level (yellow lines) and low NS1 level (green lines). The error bars represent the standard error of mean between three biological triplicates for each sample.](pone.0237141.g002){#pone.0237141.g002}

[Fig 3](#pone.0237141.g003){ref-type="fig"} shows the changes in impedance measured from pulmonary MECs incubated with 20 serum samples, five from each of the categories of HC, DWOWS, DWWS and SD. Upon introduction of sera, the MECs responded in a similar manner in all samples, starting with a slight increase in impedance and peaked at 1--2 hpi, followed by a reduction in impedance. However, the pattern varied between categories. In HC, the impedance fluctuated but maintained at a similar or above the level of the untreated cells. In DWOWS, all five samples increased the impedance of the MECs across 72 hours regardless of the level of NS1 in the samples. In DWWS, the changing pattern varied between samples, however the level of leakage did not correlate with NS1 level. MECs incubated with sample W1 with high NS1 concentration maintained its impedance at a similar level with the untreated cells, while another sample with high NS1 level (sample W2) induced a reduction in impedance below control level up to 72 hours, showing a similar modulation with MECs incubated with a sample of low NS1 level (sample W5). The two remaining samples which consisted of one sample with medium NS1 level (sample W3) and one sample with low NS1 level (sample W4), showed a similar modulation to the MECs where the impedance reduced up to 24 hours, followed by an increase of impedance over control levels across the remaining 36 hours. In SD, the MECs incubated with all sera showed a similar changing pattern in impedance, where the impedance reduced gradually after 1 hpi and eventually dropped below control levels from 36 hpi onwards.

![Normalized real time impedance changes in [pulmonary MECs]{.ul} incubated with serum samples from the category of (A) Healthy individuals (HC), (B) dengue without warning signs (DWOWS), (C) dengue with warning signs (DWWS) and (D) severe dengue (SD). Five serum samples from each dengue category consisted of samples with high NS1 level (red lines), medium NS1 level (yellow lines) and low NS1 level (green lines). The error bars represented the standard error of mean between three biological triplicates for each sample.](pone.0237141.g003){#pone.0237141.g003}

The changes in impedance of retinal MECs incubated with five serum samples from each category are presented in [Fig 4](#pone.0237141.g004){ref-type="fig"}. Similar to other two MECs, cells treated with sera from HC did not differ much with untreated cells. Samples from DWOWS induced an increase in the impedance upon the introduction of the sera at a higher magnitudes as compared to DWWS and SD, and the impedance reduced gradually but was maintained above the control levels across 72 hours. Samples with lower NS1 concentration did not modulate the MECs as much in comparison to samples with higher NS1 concentration, where the impedance fluctuated the least and maintained similarly to the untreated cells. However, the impact of NS1 in causing leakage is not conclusive as the samples from SD with low NS1 concentration was able to cause leakage at 60 hpi, but the samples with high NS1 level in the same category induced leakage later at 68 hpi.

![Normalized real time impedance changes in [retinal MECs]{.ul} incubated with serum samples from the category of (A) Healthy individuals (HC), (B) dengue without warning signs (DWOWS), (C) dengue with warning signs (DWWS) and (D) severe dengue (SD). Five serum samples from each dengue category consisted of samples with high NS1 level (red lines), medium NS1 level (yellow lines) and low NS1 level (green lines). The error bars represent the standard error of mean between three biological triplicates for each sample.](pone.0237141.g004){#pone.0237141.g004}

Cytokines highly expressed in dengue patients did not correlate with disease severity {#sec012}
-------------------------------------------------------------------------------------

Cytokine profiling was performed on 40 serum samples from four categories, HC, DWOWS, DWWS and SD ([Fig 5](#pone.0237141.g005){ref-type="fig"}). Most of the studied cytokines including CCL2, CCL5, CCL20, CD25, CXCL1, CXCL5, CXCL9, CXCL10, CXCL11, IL-18, TNF-α and VEGF-A, were highly expressed in dengue patients as compared to healthy individuals. The mean of concentrations of CCL2, CCL20, CXCL1, CXCL6, CXCL9 and TNF-α was higher in patients with SD, while CCL5, CXCL10, CXCL11 and IL-18 were expressed at lower levels in patients with SD, however, the differences were not significant.

![Comparison of serum levels of cytokines, chemokines, adhesion molecules and growth factors in HC and dengue patients, as well as patients in the categories of DWOWS, DWWS and SD.\
Student's T test was used to compare between HC and dengue cases, then across all three patient groups for significant difference represented by a p value less than 0.05, where \*\<0.05, \*\*\<0.01, \*\*\*\<0.001 and \*\*\*\*\<0.0001.](pone.0237141.g005){#pone.0237141.g005}

Severity-specific expression of HMGB-1 and ICAM-1 in dengue patients {#sec013}
--------------------------------------------------------------------

Cytokine/chemokine HMGB-1 and adhesion molecule ICAM-1 were expressed significantly higher in patients with SD and the comparison is shown in [Fig 6](#pone.0237141.g006){ref-type="fig"}. The mean concentration of HMGB-1 was highest in patients with SD, however, the difference in expression between HC and dengue cases were not significant, making the role of this cytokine in dengue pathogenesis inconclusive. On the other hand, ICAM-1 was expressed significantly higher in dengue cases than in healthy individuals, and the mean concentration was significantly higher in SD patients as compared to DWOWS and DWWS.

![Comparison of serum levels of HMGB-1 and ICAM-1 in HC and dengue patients that were further categorized into DWOWS, DWWS and SD according to disease severity.\
The significant differences in the expression level between the categories were determined using Student's T test and a p value of less than 0.05 representing significantly lower or higher, indicated by \*\<0.05, \*\*\<0.01, \*\*\*\<0.001 and \*\*\*\*\<0.0001.](pone.0237141.g006){#pone.0237141.g006}

Metabolic expression in dengue patients {#sec014}
---------------------------------------

QTOF-LCMS was performed to compare the pattern of differential metabolic expression among DWOWS, DWWS and SD categories. Two dimensional PCA analysis revealed no outliers and the samples in the same category were tightly clustered. A total of 35,042 compounds were detected from 40 samples, where 1377 compounds were known metabolites identified based on their molecular weight and retention time crosschecked with Agilent database. Fold change (FC) analysis and one-way ANOVA was performed and a total of 500 metabolites met the standard of FC \> 2.0 and p \< 0.05 subjected to hierarchical clustering by complete linkage. The expression and regulation of metabolites present in the serum from each category is summarized in supplementary [S1 Table](#pone.0237141.s001){ref-type="supplementary-material"}. The heat map of 40 samples ([Fig 7iA](#pone.0237141.g007){ref-type="fig"}) showed that HC (blue) and DWOWS (green) were clustered together, separated from the cluster of DWWS (yellow) and SD (red). The clustered heat map based on four categories ([Fig 7iB](#pone.0237141.g007){ref-type="fig"}) showed that the same cluster of metabolites were up-regulated while different cluster of metabolites were down-regulated in the three dengue categories (DWOWS, DWWS and SD).

![i) Hierarchical complete linkage clustered heat map of 500 metabolites met the requirement of FC \> 2.0 and p \< 0.05. Clustering based on individual samples (A) and categories (B) revealed the similarity as well as the differential metabolic expression in HC/DWOWS and DWWS/SD. ii) Volcano plot comparing p value against fold change of (A) DWOWS, (B) DWWS and (C) SD as compared to HC, and the top regulated metabolites in each category. A higher number of metabolites were up-regulated in dengue patients from all three categories compared to down-regulated metabolites. iii) Venn diagrams of (A) up-regulated and (B) down-regulated metabolites in DWOWS, DWWS and SD as compared to HC, and the top regulated metabolites in each category. DWOWS, DWWS and SD shared high commonality in the up-regulated metabolites, however, no metabolite was commonly down-regulated in all the categories.](pone.0237141.g007){#pone.0237141.g007}

Filtering by volcano plot ([Fig 7ii](#pone.0237141.g007){ref-type="fig"}) revealed the differential metabolic expression of DWOWS, DWWS and SD as compared to HC in term of FC and significant difference. A total of 215, 239 and 220 metabolites were up-regulated in DWOWS, DWWS and SD, respectively, while a smaller number of metabolites were down-regulated in all categories (17 in DWOWS, 4 in DWWS and 15 in SD).

The up-regulated and down-regulated metabolites were further analysed into Venn diagrams ([Fig 7iii](#pone.0237141.g007){ref-type="fig"}), where metabolites that were expressed only in each category (DWOWS, DWWS and SD) were identified. As many as 49, 47 and 47 metabolites were up-regulated only in DWOWS, DWWS and SD respectively, while DWOWS, DWWS and SD specifically down-regulated 17, 4 and 15 metabolites respectively, and no metabolite was commonly down-regulated in all the three categories.

Pathway analysis was performed on metabolites that were expressed specifically in each category of DWOWS, DWWS and SD and the most regulated pathways were arranged according to the percentages of metabolites involved in each pathway ([Fig 8](#pone.0237141.g008){ref-type="fig"}). The findings revealed that majority of the regulated metabolites are involved in lipid metabolism pathway. Of the total metabolites, 71% in DWOWS, 44% in DWWS and 61% in SD were involved in lipid metabolism pathway. In DWOWS, most of the metabolites were involved in bone formation and amino acid metabolism, and included metabolites that originate from plant and drug compounds. In DWWS, 17% of the metabolites were involved in cell signalling pathway for apoptosis, membrane permeability and ROS production. Another 17% of the metabolites were involved in amino acid metabolism including glycine, serine, betaine and methionine metabolism. In SD, 23% of the metabolites were plant derived, exogenous to the host. These metabolites include triterpenoids, isoquinolines, triacylglycerols, flavonoids, phenylpropenes and chalcones originated from plant such as bush banana, compositae flower, mountain toatoa, *Tiliacora racemosa*, *Camptotheca acuminata* and citrus, where some have been categorized as medicinal plant to have antibiotic and antioxidant properties. Further analysis of the metabolites in lipid metabolism pathway revealed that most of the metabolites (50%) in DWOWS involved fatty acid metabolism, while 63% and 70% of the metabolites in DWWS and SD respectively involved phospholipid metabolism.

![Pathway analysis of metabolites specifically regulated in patients from categories of DWOWS, DWWS and SD.\
A) The number of metabolites involved in the pathways were calculated as percentage (%) of the total metabolites regulated in each category. B) Metabolites involved in lipid metabolism pathway were further categorized into lipid associated metabolism pathways.](pone.0237141.g008){#pone.0237141.g008}

The metabolites, namely L-isoleucine, L-phenylalanine, 2-amino-3-methyl-1-butanol, C16 sphinganine, indoleacrylic acid and neoabietic acid, were detected in most of the healthy individuals (70--100%), but had a lower prevalence in dengue patients ([Fig 9](#pone.0237141.g009){ref-type="fig"}). Among the six metabolites, L-isoleucine, L-phenylalanine, 2-amino-3-methyl-1-butanol and C16 sphinganine had the lowest prevalence in patients with SD (20--50%), and the level of expression of C16 sphinganine was significantly lower in SD when compared with DWWS with a p value of \<0.05. Although 2-amino-3-methyl-1-butanol was not detected in all dengue patients, the concentration of this metabolite was significantly higher in those dengue patients with a p value of \<0.01. On the other hand, the prevalence of neobietic acid was lower in dengue patients, however SD had the highest prevalence among the three dengue categories.

![The percentage of patients expressing A) L-isoleucine, B) L-phenylalanine, C) 2-amino-3-methyl-1-butanol, D) C16 sphinganine, E) indoleacrylic acid and F) neoabietic acid and the abundance of expression of these metabolites for each individual in categories of HC, DWOWS, DWWS and SD. Student's T test was used to compare HC and dengue cases, as well as among the three dengue groups for significant difference in abundance, represented by a p value less than 0.05, where \*\<0.05 and \*\*\<0.01. Individuals with zero abundance are not shown on the dot plot.](pone.0237141.g009){#pone.0237141.g009}

Two metabolites, Etn-1-P-cer and Palmitic amide ([Fig 10](#pone.0237141.g010){ref-type="fig"}) were noted to be present at higher levels in dengue patients as compared to healthy individuals. Etn-1-P-cer was detected in 20% of the healthy individuals, 40% of both DWOWS and DWWS and in 70% of the patients with SD, while 50% of the healthy individuals, 70% of the patients with DWOWS and 80% of both the patients with DWWS and SD had palmitic amide detected in their serum samples. However, the abundance of these metabolites detected was not significantly different among the three dengue categories.

![The percentages of patients expressing A) Etn-1-P-cer and B) palmitic amide, and the abundance of expression of these metabolites for each individual in the categories of HC, DWOWS, DWWS and SD. The significant difference in expression was determined using Student's T test to compare between HC and dengue cases as well as among the three dengue groups, however the differences were not significant with p values were more than 0.05. Individuals with zero abundance are not shown on the dot plot.](pone.0237141.g010){#pone.0237141.g010}

Glycocholic acid and glyco-ursodeoxycholic acid was detected only in dengue patients but the prevalence was low ranging from 30--40% in each category ([Fig 11](#pone.0237141.g011){ref-type="fig"}). The mean concentration of these metabolites was higher in patients with SD, however the difference of expression was not significant as compared to DWOWS and DWWS.

![The percentages of patients expressing A) glycocholic acid and B) glycol-ursodeoxycholic acid and the abundance of expression of these metabolites for each individual in the categories of HC, DWOWS, DWWS and SD. Student's T test was used to determine the significant difference in expression among DWOWS, DWWS and SD, however the differences were not significant as the p values were more than 0.05. Individuals with zero abundance are not shown on the dot plot.](pone.0237141.g011){#pone.0237141.g011}

Discussion {#sec015}
==========

Our study showed that NS1 alone can induce loss of barrier function in microvascular endothelium in a dose dependent manner. Based on ECIS measurement, the magnitude of vascular leakage observed was positively correlated with the concentration of NS1 protein, especially pronounced in pulmonary MECs. However, serum NS1 level in dengue patients did not directly correlate to the extent of vascular leakage observed in MECs, indicating that there might be other factors overshadowing the direct effect of circulating NS1 to the endothelium, but still leading to the vascular leakage observed in patients with SD. The association of NS1 antigen with disease severity in dengue virus infection have been commonly studied, however the results are contradictory and inconclusive. Several studies reported that the presence of circulating NS1 antigen was associated with a higher risk of developing severe manifestations and the serum NS1 levels were higher in patients with SD than those with mild dengue fever \[[@pone.0237141.ref016], [@pone.0237141.ref017], [@pone.0237141.ref043]\]. On the other hand, there is a paper showing that low NS1 antigen level instead was associated with more severe form of dengue \[[@pone.0237141.ref021]\]. Furthermore, studies also reported that there is no significant difference in NS1 concentration among patient groups of different disease severity \[[@pone.0237141.ref022]\], which is in agreement with our study, highlighting the complicated pathogenesis of dengue virus infection.

The loss of barrier function observed in the NS1-treated MECs has also been reported in other studies where NS1 was shown to degrade endothelial glycocalyx components \[[@pone.0237141.ref020], [@pone.0237141.ref044]\], increase the secretion of angiopoietin-2 and disrupt the function of junctional protein VE-cadherin \[[@pone.0237141.ref045]\] in endothelial cells, leading to hyper-permeability and endothelial dysfunction. However, the clinical effect of serum NS1 on endothelial barrier function has not been well studied and our results showed that the effect of NS1 in inducing vascular leakage was not prominent in clinical cases as compared to its direct stimulation on MECs, proposing a larger involvement of other factors such as cytokines or metabolites produced during dengue virus infection in the host.

To address the presence of factors other than NS1 protein in determining disease severity in clinical cases, 40 serum samples were subjected to cytokines and metabolomics profiling. Among all the studied cytokines, HMGB-1 and ICAM-1 were found to be correlated with disease severity, where the expression was significantly higher in patients with SD. HMGB-1 (high mobility group box 1) is a DNA binding protein that regulates innate immunity and partially the adaptive immunity \[[@pone.0237141.ref046]\]. This protein can be released into the extracellular environment passively upon apoptosis or necrosis of cells \[[@pone.0237141.ref047]\] or actively by activated macrophages and monocytes \[[@pone.0237141.ref048]\], which then functions as a pro-inflammatory cytokine in the inflammatory response positive feedback loop to stimulate endothelial cells for cytokine and chemokine production \[[@pone.0237141.ref049]\]. HMGB-1 had also been shown to induce the production of ICAM-1 in endothelial cells \[[@pone.0237141.ref050]\], which was also expressed significantly higher in patients with SD in our study. ICAM-1, an intercellular adhesion molecule, plays an important role in leukocytes transmigration at the sites of activated endothelial cells and the formation of immunological synapse during cellular immune responses \[[@pone.0237141.ref051], [@pone.0237141.ref052]\]. Previous studies have reported the roles of HMGB-1 and ICAM-1 in dengue virus infection where both proteins were released by dengue infected endothelium or immune cells \[[@pone.0237141.ref039], [@pone.0237141.ref053]\] and increased permeability of endothelial cells leading to vascular leakage \[[@pone.0237141.ref054], [@pone.0237141.ref055]\]. They were detected at a higher concentration in dengue patients \[[@pone.0237141.ref056], [@pone.0237141.ref057]\], while HMGB-1 was also detected in the peripheral organs of dengue fatal cases \[[@pone.0237141.ref038]\], which further justified the role of HMGB-1 and ICAM-1 in the progression of severe dengue.

Metabolomics study using QTOF-LCMS revealed that metabolites specifically regulated in DWOWS, DWWS and SD mostly interact with lipid metabolism pathway. DENV has been shown to mediate lipid synthesis and metabolism in their replication cycles \[[@pone.0237141.ref058]\] by taking advantage of the production of double membrane vesicles during autophagy for efficient replication \[[@pone.0237141.ref059]\]. In patients with DWOWS, most of the metabolites are involved in fatty acid metabolism for energy generation and to create triglycerides, phospholipids and other important membrane constituents \[[@pone.0237141.ref060]\], probably to maintain cellular processes to repair damages upon dengue virus infection \[[@pone.0237141.ref061]\]. On the other hand, patients with DWWS and SD expressed large number of metabolites that are involved in phospholipid metabolism pathway, which regulates the formation and function of the membrane bilayer \[[@pone.0237141.ref062]\]. Phospholipids are a class of lipids consist of a phosphate group that can form lipid bilayers and function as the major components of cell membrane \[[@pone.0237141.ref063]\]. Components from different class of phospholipids such as phosphatidylcholine, phosphatidylglycerol and phosphatidylserine as well as phosphatidic acid, which are precursors for other more complex phospholipids were expressed differentially in dengue patients, especially those with DWWS and SD. Deregulated phospholipid metabolism is likely to be due to the changes in exogenous intake of fatty acid from patient's diet during infection or altered activities of lipid-metabolizing enzymes induced by DENV \[[@pone.0237141.ref064]\]. Perturbations of the phospholipid metabolism might contribute to the destabilization of membrane permeability during dengue virus infection \[[@pone.0237141.ref065]\]. Furthermore, patients with SD specifically expressed metabolites originated from sphingolipid metabolism pathway, where sphingolipids are found mainly in the membranes of brain and nervous cells. Altered sphingolipid metabolism might lead to rearrangement of membrane components which has been associated with various neurological diseases \[[@pone.0237141.ref066]\] that might possibly link to the rare neurological complications, such as brachial neuropathy or encephalopathy observed in patients with SD \[[@pone.0237141.ref067]\].

Our metabolomics findings have also identified amino acids such as L-isoleucine, L-phenylalanine and 2-amino-methyl-1-butanol, which are essential in the biosynthesis of proteins were lacking in the sera of dengue patients, with the lowest prevalence in patients with SD. Changes in the plasma free amino acid pattern, indicating infection-related alterations of amino acid metabolism, has been reported in dengue virus infection \[[@pone.0237141.ref068]\]. The disruption of protein biosynthesis pathway might be due to DENV-induced changes in the host cell transcriptional and translational machinery \[[@pone.0237141.ref069]\] involved along the DENV replication cycle \[[@pone.0237141.ref070]\]. Besides, cell membrane-associated metabolites such as C16 sphinganine and indoleacrylic acid were also found to have a lower prevalence in dengue patients. Interaction of DENV with cellular membranes for viral replication during infection has been widely reported \[[@pone.0237141.ref071]\]. Since membrane-associated metabolites modulate membrane integrity by altering the biophysical properties of cell membrane \[[@pone.0237141.ref072], [@pone.0237141.ref073]\], the differential expression of these metabolites in dengue patients might contribute to the loss of endothelial barrier function leading to vascular leakage observed in dengue patients.

Contrarily, some metabolites were detected at a higher prevalence in dengue patients, where healthy individuals expressed such metabolites at a lower occurrence or none at all. Etn-1-P-cer and palmitic amide, the membrane fatty acids in the family of sphingolipids, were detected higher in dengue patients, especially in patients with SD. Studies have shown that sphingolipids and other bioactive signalling molecules were up-regulated in DENV infected mosquitoes cells \[[@pone.0237141.ref065]\] and enhanced trans-endothelial cell permeability in DENV infected microvascular cells \[[@pone.0237141.ref074]\]. Sphingolipids consist of highly complex and distinct interconverting bioactive lipids that function as signalling molecules for cell migration, adhesion and inflammatory responses, which also form the chemically resistant and mechanically stable outer leaflet of the membrane bilayer \[[@pone.0237141.ref075], [@pone.0237141.ref076]\]. The abundance of bioactive lipids from sphingolipids in the patient's sera indicate a disruption of sphingolipids biosynthesis and metabolism, possibly contributing to metabolic disorders, immune dysfunction, skin integrity and in our case, perhaps vascular diseases \[[@pone.0237141.ref077]\]. Two metabolites involved in bile acid synthesis were also detected only in dengue patients, albeit at a low prevalence. The metabolism of glycocholic acid, a conjugated primary bile acid synthesized by the liver \[[@pone.0237141.ref078]\] and glycol-ursodeoxycholic acid, a secondary bile acid enzymatically modified by microbiota \[[@pone.0237141.ref079]\], was differentially expressed in dengue patients. Impaired bile acid homeostasis has been shown to contribute to the pathogenesis of liver diseases \[[@pone.0237141.ref080]\], including acute liver failure that has been viewed as one of the indication of severe dengue \[[@pone.0237141.ref081]\]. Furthermore, these two metabolites have a role in fat emulsification and cholesterol regulation; the interference in their metabolism might modulates cholesterol biosynthesis and change the lipid profile of dengue patients during infection \[[@pone.0237141.ref082], [@pone.0237141.ref083]\]. Overall, our findings are in agreement with a serum metabolomics investigation of humanized mouse model where the major perturbed pathways included sphingolipid, amino acid and bile acid metabolism during dengue virus infection \[[@pone.0237141.ref084]\].

The interplay between host immune responses and metabolic processes, especially the interactions between inflammation and lipid metabolism has been reported to exacerbate the development of several diseases including atherosclerosis \[[@pone.0237141.ref085]\], rheumatoid arthritis \[[@pone.0237141.ref086]\], as well as infections by pathogens such as *chlamydia trachomatis* \[[@pone.0237141.ref087]\] and hepatitis C virus \[[@pone.0237141.ref088]\]. Modified lipids, fatty acids and lipoproteins have shown to interfere with inflammatory response and directly affect immune cell activation \[[@pone.0237141.ref089], [@pone.0237141.ref090]\], while altered inflammatory signalling directly impacts lipid metabolism in metabolic and immunity diseases \[[@pone.0237141.ref091]\]. Although the interconnection between inflammatory cytokines and lipid-associated metabolites during DENV infection has not been well reported, the cytokines highly expressed in dengue patients from this study such as CCL2, CCL5, CCL20, CXCL1, CXCL5 and IL-18 have been shown to associate with the disruption of lipid metabolism in other diseases, however, most of the studies were done with a mouse model. The blockage of CCL2 receptor, CCR2 has been shown to induce phenotypic changes of adipocytes leading to improved lipid metabolism in the kidney of mice with diabetic nephropathy; the high level of CCL2 observed in DENV infection might interfere lipid metabolism through activation of CCR and its downstream pathway \[[@pone.0237141.ref092]\]. Furthermore, high level of IL-18 increased AMPK signalling leading to increased fat oxidation and might correlates with reduced concentration of circulating triglycerides \[[@pone.0237141.ref093], [@pone.0237141.ref094]\]. CXCL1, which is functional equivalent with IL-18, was also shown to enhance fatty acid oxidation at high concentration \[[@pone.0237141.ref095]\]. Although some of the cytokines have not been reported on its effect on lipid metabolism, they are known to associate with lipid-associated diseases. For instance, the expression of CCL5 and CCL20 has been associated with fatty liver disease \[[@pone.0237141.ref096], [@pone.0237141.ref097]\], while CXCL5 is an adipose tissue derived factor associated with obesity \[[@pone.0237141.ref098]\]. The interference of these cytokines with lipid metabolism in other diseases provides insights on the plausible alteration of lipid metabolism caused by cytokine storm during DENV infection, and the possibility of this leading to the disruption of cell membrane permeability merits further investigation.

One of the principle caveats for this study is the fact that ECIS measurement does not provide direct information at the molecular level as the readings are generated based on the interaction between electric current flows and cell morphology changes. However, this study focused only on the cellular level to compare the direct or indirect stimulation of NS1 in MECs, hence, it is thus informative at the beginning of our experimental series to obtain input for the construction of a feasible hypothesis. Another limitation of the study was the small sample size of only 40 sera due to the difficulties in obtaining more samples from patients with SD. Although the study has less statistical power, we were able to identify a few cytokines and metabolites that would provide insight on the role of host factors in the pathogenesis of dengue virus infection and possibly determine or predict disease severity that should be assessed using a larger sample size in the future.

Conclusions {#sec016}
===========

Our study revealed that dengue NS1 protein was able to induce the loss of barrier function of the microvascular endothelium in a dose dependent manner. However, the level of NS1 did not correlate with the extent of vascular leakage observed in the microvascular endothelium treated with serum samples from patients with dengue virus infection. This finding suggested the presence of other host factors that might overshadow the direct effect of NS1 in inducing vascular leakage during dengue virus infection. Most of the cytokines that were highly expressed in dengue patients including CCL2, CCL5, CCL20 and CXCL1 are involved in leukocyte infiltration where the rearrangement of junctional complex proteins such as ICAM-1, which was detected significantly higher in patients with SD, may lead to the disruption of inter-endothelial junctions. Altered lipid metabolism was detected in dengue patients, where severe manifestations were observed in patients with DWWS and SD. This might be associated with phospholipid metabolism, which may affect the membrane permeability of cells including the microvascular endothelium. Our study further highlighted the complexity of dengue as no single factor alone, either viral or host, can be responsible for the progression of severe dengue, nor can be used as prognostic marker for disease severity. In this circumstance, the identification of these altered metabolites could facilitate dengue diagnosis or be used as a potential target for new therapeutic options.
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Response: For cytokine profiling, the precision and reproducibility of the assays were assured by calculating the coefficient of variance of the replicates. Then we proceeded to access the significant differences of the cytokine expression profile between the categories using student's T test. For untargeted metabolomics, all the statistical analysis was performed using the chemometrics software Mass Profiler Professional designed for the such purposes.

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Response: Thank you.

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study by Soe and collegues presents a thorough characterization of the effect of patients' sera with a broad range of disease severity, or NS1 antigen itself, on the integrity of microvascular endothelial cells. In the attempt of clarifying the ongoing debate on the role of NS1 in disrupting functional endothelial barrier, and its causal relation with Dengue disease progression, the authors further profiled the level of several cytokines and multiple metabolites using a multiplex flow cytometric assay and untargeted metabolomics, respectively. Overall the study is clearly written, results presented in an intelligible fashion and discussed in the context of the vast body of literature on the topic. Although no major breakthrough is presented, and most of the results are actually supportive of a lack of correlation between Dengue disease severity and any of the analysed variables (NS1 levels, pro-inflammatory cytokines or metabolites), the presented results are still important and worth publishing as they consolidate the notion that no specific/individual factor present in the sera (either of viral or cellular origin) can be clearly and unequivocally used as prognostic marker for disease severity. Furthermore, the study present a metabolic-based survey of patients sera, which have been well-characterized/normalized (i.e. based on NS1 levels and IgG), and therefore could be of relevance for the community.

Major points:

My only experimental concern relates to the ECIS experiment, with respect to the control used and the degree of details provided in the methods section.

More specifically (related to Fig.1-3):

\- The purified NS1 protein used in Fig.1 was of which origin (i.e. bacterial, mammalian..etc), to which extent was purified, and in which diluent was diluted? This information is quite critical as it sets the ground for interpretation of the assay in the following figures.

Response: The purified NS1 protein is a recombinant dengue virus serotype 1 NS1 protein of sequence strain Nauru/Western Pacific/1974 expressed in 293 human cells. It is a purified recombinant protein with a C-terminal 6x His-tag and purity of \>95% by SDS PAGE analysis diluted in buffer solution Dulbecco's phosphate buffered saline, which was further diluted during the experiment using the respective media of each cell line used. The above information has been added to the methodology.

Furthermore, in order to exclude additional factors, the purified NS1 protein used here should have been diluted in healthy individual sera (perhaps this information is provided, though I could not find it in the text or the methods section).

Response: Healthy individual served as negative control for the experiment and hence it contains no NS1 antigen. It was included to compare against the patients from the three categories of dengue. On the other hand, the purified NS1 protein was included not only to investigate the effect of viral factor (NS1) on endothelium, but also as a comparison for the different NS1 level present in the serum samples. The characteristics of all samples were included in table 1.

\- What are the positive ctrls used in this assay? (probably a known disruptor of endothelial barrier should be included here to show the sensitivity of the assay)

Response: A positive control was not included in the experiment as a standard disruptor of the endothelial barrier is yet to be established. We therefore included the purified NS1 protein to compare the modulation of endothelial barrier against patient sera that contain NS1 antigen at varying level with the presence of other host factors.

\- What is the dynamic range of this assay? Without the ctrls described above, is difficult to assess whether the amplitude of the changes described in Fig. 1-3 is significant, and whether the variance across and within groups is acceptable.

Response: The use of ECIS system allow us to monitor real-time cell barrier function, cell to cell adhesion and cell to matrix interactions, which is an incredibly sensitive (described below) method for evaluating barrier function of cells in vitro. It was used to compare the relative pattern of modulation between treated and untreated cells, rather than an absolute reading on the impedance changes. The results presented in this manuscript have been normalized and standardized to eliminate the effect of any gross influences during the experiment. The values were detected at multiple frequencies for three biological replicates with 10 detection points each, and the standard error of the mean was plotted as error bar in Fig. 1-3. The statistical measures included the normalization to a cell-free electrode, standardization of the fluctuations due to cell mobility such as micromotion, and a mathematical model that was implied to determine the changes in the endothelial barrier function. The readings were also normalized to the untreated endothelial cells and therefore, only values with significant difference as compared to the untreated cells were plotted in the graphs to represent the real-time changes of the barrier function of the treated cells.

The following studies provide information on the sensitivity of ECIS system with regards to detecting low viral effects:

1\. Mouse brain MEC infected with West Nile virus at MOI of 0.01 increased TEER up to 6 hours \[1\]

2\. Reduced TEER was observed in Mouse Hepatitis Virus type 3-infected brain MEC at a MOI of 0.1 up to 72 hours \[2\]

3\. Human Bocavirus-1 at the MOI of 0.001, 0.01, 0.1, 1, 10 and 100 reduced the TEER of human airway epithelial cells \[3\]

The studies above on the infection kinetics of different type of viruses on endothelial / epithelial cells provide information that the ECIS system is sensitive enough to detect small modulation of epithelial/endothelial cells infected with viruses at a relatively low MOIs.

Limitation of the ECIS has also been included in the last paragraph of the discussion.

References quoted:

\[1\] Lazear et al. (2015) Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier, Sci Transl Med, 7(284): 284ra59.

\[2\] Bleau et al. (2015) Brain Invasion by Mouse Hepatitis Virus Depends on Impairment of Tight Junctions and Beta Interferon Production in Brain Microvascular Endothelial Cells, J Virol, 89(19): 9896-9908.

\[3\] Deng et al (2013) In Vitro Modeling of Human Bocavirus 1 Infection of Polarized Primary Human Airway Epithelia, J Virol, 87(7): 4097-- 4102.

Minor points:

Figures 7-10 could be easily grouped in one figure without losing clarity.

Response: Figures 7-9 have been combined into Figure 7 and be divided into parts i), ii) and iii). To better discuss the results for pathway analysis as a separated outcome, Figure 10 was kept as a single figure and has been changed to Figure 8.

Furthermore it would be important for the reader, to include in the volcano plots and in the Venn diagrams (i.e. Fig.8-9) full names of at least some of the top metabolites identified as significantly regulated by one or more classes. These figures as such are currently not conveying any meaningful information.

Response: We agree with the reviewer's comment, as such, the top regulated metabolites of each category have been added into the figures.

Figures-7-13: The raw data and related statistical analysis of MS results should be presented in full in supplementary tables, to provide the reader with a mining-friendly resource. This is one of novelty points of the study, but it is virtually hidden as only selected candidates are presented in details in Fig.11-13.

Responses: The raw data of metabolites present in serum samples from each category of DWOWS, DWWS and SD has been presented in supplementary S1 table (at end of manuscript).
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PONE-D-19-24309R1

Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection

PLOS ONE

Dear Dr. Sekaran,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically try to answer the two reviewers comments about the manuscript organisation and the number of sample tested. As noted you results are in accordance with other studies that NS1 is not a potential marker for early diagnosis of dengue. 

your title might be: Correlation of host inflammatory cytokines and immune-related

metabolites, but not viral NS1 protein, with disease severity of dengue virus infection

Please submit your revised manuscript by Jul 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Pierre Roques, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: No

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: In manuscript titled "Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection", the authors tested sera from 40 dengue patients, and intended to evaluate the relation between the presence of NS1/host cytokines/host metabolites and the severity of dengue diseases. The overall conclusion is that no significant correlation has been found between the two. Therefore their original intention to develop a potential marker for early diagnosis of dengue failed. The data collected in this manuscript can be valuable to understanding the dengue diseases and to the broader virology field if some of the essential controls are included in the experiments.

1\) Introduction lacks a clear elaboration of the purpose of the study. It did not establish a clear rationale that supports the logic of testing NS1. For example, in lines 48-50, the authors said "Hence, this study aims to investigate the role of the viral non-structural 1 (NS1) protein, the inflammatory cytokines and the immune-related metabolites in contributing to the degree of severity of dengue virus infection". However, the sentence before this conclusion is broad statement "The pathogenesis of severe dengue is theorized to be due to the intricate interactions between viral factors, host genetics and host immune activation" with no facts or details to explain why NS1 needs to be tested. More information should be included to elaborate the significance of why these experiments are done.

2\) Some information introduced in the discussion, such as the first paragraph of discussion explaining ECIS, should be moved to introduction. It is strange to explain a method in discussion after the results have already been presented.

3\) Figure 1 showed purified NS1 increases vascular permeability in pulmonary MEC. Figures 2-4 did not show substantial differences when they used different groups of patient sera on different cells. To examine whether NS1 has the potential to become a diagnostic marker for dengue, an experiment that dilute the purified NS1 in uninfected human sera would give a clear answer. It is quite possible that certain sera composition blocks the NS1 effect.

4\) The authors did metabolites analysis with the patient sera. However, without a control of healthy human sera, these data have no meaning for future analysis. Another possible control is to use human sera from another viral infection to show whether conclusion drawn from Figure 7-10 is dengue specific or not.

Reviewer \#3: The manuscript Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection presented by Sekaran SD et al, is an interesting study regarding an important cause of disease, dengue.

It is a laboratory study that analyze the effect of the addition of Dengue sera to Electrical cell-substrate impedance senting (ECIS). Also, the citokynes and metabolic profile were measured.

I have several question.

1\. The primaty and secondary dengue have differences in several geographic areas. The authors did no give any commentary about that.

2\. The ECIS was performed with only 5 serum of dengue cases and none the original NS1 Ag was tested.

3\. The cytokine profile were determine in only 40 serum (including from patients without alarm signs, with alarm signs or severe dengue). The authors need to include more patients.

4\. The same observations are done regarding the metabolic expression in dengue patients.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

Reviewer \#3: Yes: Antonio Arbo, MD, MSc

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237141.r004

Author response to Decision Letter 1

16 Jun 2020

Response to Reviewers:

Reviewer \#2: In manuscript titled "Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection", the authors tested sera from 40 dengue patients, and intended to evaluate the relation between the presence of NS1/host cytokines/host metabolites and the severity of dengue diseases. The overall conclusion is that no significant correlation has been found between the two. Therefore, their original intention to develop a potential marker for early diagnosis of dengue failed. The data collected in this manuscript can be valuable to understanding the dengue diseases and to the broader virology field if some of the essential controls are included in the experiments.

1\) Introduction lacks a clear elaboration of the purpose of the study. It did not establish a clear rationale that supports the logic of testing NS1. For example, in lines 48-50, the authors said "Hence, this study aims to investigate the role of the viral non-structural 1 (NS1) protein, the inflammatory cytokines and the immune-related metabolites in contributing to the degree of severity of dengue virus infection". However, the sentence before this conclusion is broad statement "The pathogenesis of severe dengue is theorized to be due to the intricate interactions between viral factors, host genetics and host immune activation" with no facts or details to explain why NS1 needs to be tested. More information should be included to elaborate the significance of why these experiments are done.

Response: The role of NS1 in inducing vascular leakage have been described in the second paragraph. Nevertheless, the interactions between viral factors and host factors have been elaborated in the first paragraph to justify the rationale of investigating the correlation of viral factors and host factors with vascular leakage observed in patients with severe dengue.

2\) Some information introduced in the discussion, such as the first paragraph of discussion explaining ECIS, should be moved to introduction. It is strange to explain a method in discussion after the results have already been presented.

Response: The paragraph discussing the principle of ECIS has been moved to introduction.

3\) Figure 1 showed purified NS1 increases vascular permeability in pulmonary MEC. Figures 2-4 did not show substantial differences when they used different groups of patient sera on different cells. To examine whether NS1 has the potential to become a diagnostic marker for dengue, an experiment that dilute the purified NS1 in uninfected human sera would give a clear answer. It is quite possible that certain sera composition blocks the NS1 effect.

Response: The main objective of this manuscript is to assess the role of viral factor (NS1) and host factors (cytokines and metabolites) in contributing to the degree of vascular leakage in the microvascular endothelium during DENV infection, therefore, we focus on the sera of DENV infected patients with varying disease severity, which also contain NS1 protein at varying level. Since the findings showed that the serum NS1 level in dengue patients did not directly correlate to the extent of vascular leakage observed in MECs, we then proceeded to investigate the composition of the sera, in term of cytokines and metabolites, that might had overshadowed the effect of NS1. We have successfully identified some of the host proteins that were highly expressed in dengue patients and they might have played a bigger role as compared to NS1 in inducing vascular leakage. However, we would also like to highlight that no single factor alone should be concluded to be responsible for the progression of severe dengue, as the pathogenesis of dengue involves complex interactions between multiple factors. Nevertheless, the last paragraph of the introduction has been rephrased to better describe the main objectives of this study.

4\) The authors did metabolites analysis with the patient sera. However, without a control of healthy human sera, these data have no meaning for future analysis. Another possible control is to use human sera from another viral infection to show whether conclusion drawn from Figure 7-10 is dengue specific or not.

Response: Control of healthy human sera was included for all the experiments of ECIS, cytokines and metabolomics profiling. The expression of cytokines and metabolites in dengue patients was compared against the expression profile of healthy individuals. The methodology of sample collection and selection, as well as the results of samples characteristics have been revised to better explain the samples used in this study.

 

Reviewer \#3: The manuscript Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection presented by Sekaran SD et al, is an interesting study regarding an important cause of disease, dengue.

It is a laboratory study that analyze the effect of the addition of Dengue sera to Electrical cell-substrate impedance sensing (ECIS). Also, the cytokines and metabolic profile were measured.

I have several questions.

1\. The primary and secondary dengue have differences in several geographic areas. The authors did not give any commentary about that.

Response: The introduction has been revised to include the differences of primary and secondary infections in different geographic areas.

2\. The ECIS was performed with only 5 serum of dengue cases and none the original NS1 Ag was tested.

Response: For ECIS, we investigated the effect of direct stimulation of NS1 antigen on microvascular endothelium, as well as the effect of NS1 in the presence of other host factors in the patient sera towards microvascular endothelial barrier function. A total of 20 samples were used, 5 from each of the categories of healthy individual, dengue without warning signs, dengue with warning signs and severe dengue to provide an insight to the pattern of the changes in the barrier function of four microvascular endothelial cell lines in response to NS1/sera stimulation.

3\. The cytokine profile were determined in only 40 serum (including from patients without alarm signs, with alarm signs or severe dengue). The authors need to include more patients. The same observations are done regarding the metabolic expression in dengue patients.

Response: One of the limitations for this study was the small sample size of only 40 sera due to the difficulties in obtaining more samples from patients with severe dengue. Although the study has less statistical power, we were able to identify a few cytokines and metabolites that would provide insight on the role of host factors in the pathogenesis of dengue virus infection and possibly determine or predict disease severity that should be assessed with other approaches using a larger sample size in the future. This limitation has been discussed in the discussion.
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PONE-D-19-24309R2

Correlation of host inflammatory cytokines and immune-related metabolites, but not viral NS1 protein, with disease severity of dengue virus infection

PLOS ONE

Dear Dr. Sekaran,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The fact that at the end the studied population is very small taking in account all the variables as noted by the reviewers have to be indicated in the abstract as a limitation of the study. Some results confirmed previous studies from independant groups but new exploration done here remained exploratory and deserved to be confirmed or extended using independant cohort. All this limitation deserved to be highligted in the discussion but also in the conclusion of the abstract.

Please submit your revised manuscript by Aug 21 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Pierre Roques, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Because the very low number of patients studied at the end the abstract should include this information. Ie the work is interesting but exploratory and deserved to be confirmed on independant cohort concerning the ECIS assay. This is mandatory

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: 1) The authors addressed my questions. However, the newly added Figure 12 cannot be found in the paper.

2\) Now that it is clearly described in the materials and methods that the 40 samples include 30 from patients and 10 from healthy people, the sample size is really small.

Reviewer \#3: The manuscript Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection presented by Sekaran SD et al, is an interesting study regarding an important

cause of disease, dengue.

It is a laboratory study that analyze the effect of the addition of Dengue sera to Electrical cell-substrate impedance sensing (ECIS). Also, the cytokines and metabolic profile were measured.

I have several questions.

Altough the authors say that they have include the differences of primary and secondary infections in different geographic areas, in the results the differences are scarse.

Moreover, the cytokibes were determined in only 40 serum samples from four categories, HC, DWOWS, DWWS and SD. This explained that only eight serum were analized by categorie.

The metabolic expresion of dengue patients have the same difficulty. Only 40 sera were studied, correspondind to foue categories.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

Reviewer \#3: **Yes: **Antonio Arbo, MD. Institute of Tropical Medicine. Asuncion, Paraguay

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237141.r006

Author response to Decision Letter 2

18 Jul 2020

Response to Reviewers

Reviewer \#2:

1\) The authors addressed my questions. However, the newly added Figure 12 cannot be found in the paper.

Response: Figure 12 was named after the graphical abstract; it is now being renamed as Graphical abstract and was uploaded separately.

2\) Now that it is clearly described in the materials and methods that the 40 samples include 30 from patients and 10 from healthy people, the sample size is really small.

Response: This limitation is now highlighted in the abstract to state that the findings deserved to be confirmed or extended using independent cohort with a bigger sample size.

Reviewer \#3:

The manuscript Correlation of viral NS1 protein, host inflammatory cytokines and immune-related metabolites with disease severity of dengue virus infection presented by Sekaran SD et al, is an interesting study regarding an important cause of disease, dengue.

It is a laboratory study that analyzes the effect of the addition of Dengue sera to Electrical cell-substrate impedance sensing (ECIS). Also, the cytokines and metabolic profile were measured.

I have several questions.

1\) Although the authors say that they have include the differences of primary and secondary infections in different geographic areas, in the results the differences are scarce.

Response: The differences of primary and secondary infections in different geographic areas were included in the introduction as supplementary information to the topic. However, we did not include the differences between primary and secondary infections in the experiment planning as we would like to focus on the categories of disease severity.

2\) Moreover, the cytokines were determined in only 40 serum samples from four categories, HC, DWOWS, DWWS and SD. This explained that only eight serum were analyzed by categories. The metabolic expressions of dengue patients have the same difficulty. Only 40 sera were studied, corresponding to four categories.

Response: The limitation of small sample size has been included in the discussion, as we feel that the exploratory findings merits further investigation, this limitation is now highlighted in the abstract to state that the findings deserved to be confirmed or extended using independent cohort with a bigger sample size.
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Submitted filename: Response to Reviewers.docx
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22 Jul 2020

Correlation of host inflammatory cytokines and immune-related metabolites, but not viral NS1 protein, with disease severity of dengue virus infection

PONE-D-19-24309R3

Dear Dr. Sekaran,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Pierre Roques, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
